Related Experiment Video

Updated: Jun 2, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Phase 1 clinical trials for sarcomas: the cutting edge

Vivek Subbiah1, Razelle Kurzrock

  • 1Department of Investigational Cancer Therapeutics (A Phase I Program), University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA. vsubbiah@mdanderson.org

Current Opinion in Oncology
|April 27, 2011
PubMed
Abstract

Insights

Advanced sarcoma patients benefit from targeted drugs in early-phase trials. Identifying predictive biomarkers is key to translating research into clinical benefit for refractory sarcoma.

Area of Science:

  • Oncology
  • Translational Research
  • Clinical Therapeutics

Background:

  • Limited standard second-line treatments for advanced sarcoma.
  • Early-phase clinical trials offer targeted and nontargeted agents.
  • Developmental therapeutics are crucial for refractory cases.

Purpose of the Study:

  • Review recent phase 1 clinical trials in sarcoma.
  • Explore challenges in sarcoma developmental therapeutics.
  • Highlight future opportunities for targeted therapies.

Main Methods:

  • Review of published phase 1 clinical trials.
  • Analysis of novel targeted and nontargeted agents.
  • Exploration of combination therapies.

Main Results:

  • Molecularly targeted agents show efficacy in sarcoma phase 1 trials.
  • Examples include IGF1R antibodies, Apo2L/TRAIL agonists, crizotinib, cedarinib, and rexin-G.
  • Combination chemotherapy with trabectedin demonstrates efficacy in soft tissue sarcoma.

Conclusions:

  • Refractory sarcoma patients benefit from targeted drugs in phase 1 trials.
  • Sarcomas with defined translocations or specific activated kinases are promising for targeted therapy.
  • Biomarker identification for response/resistance is a primary challenge for clinical translation.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...